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significantly less than 200, probably resulted in a case-matched
population with significantly different characteristics from the
parent populations. This underscores the difficulty in studying this
particular disease entity, but also suggests that more sensitive and
specific multivariate models can be constructed to better identify
patients at risk.
Overall, notwithstanding the limitations inherent in the meth-
ods and those described above, we believe we have built a strong
case against postoperative atrial fibrillation as a predictor of
mortality. More importantly, we have raised awareness that this is
more than likely not a benign process and that it deserves more
in-depth study.
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Should We Use the Cutting Balloon
in Patients With In-Stent Restenosis?
We read with great interest the elegant randomized study of
Albiero et al. (1) comparing cutting balloon with conventional
balloon angioplasty in a large cohort of patients with in-stent
restenosis (ISR). The researchers found that recurrent restenosis
rate (29.8% vs. 31.4%) and major adverse cardiac events at seven
months (16.4% vs. 15.4%) were similar in the two groups.
In-stent restenosis constitutes a major clinical problem and a
therapeutic dilemma with a high recurrence risk (2). In this
challenging setting, published retrospective studies have consis-
tently demonstrated the favorable outcome provided by different
mechanical strategies that have emerged as attractive alternatives to
conventional balloon angioplasty. Therefore, systematic use of
these specific devices (laser, rotational atherectomy, cutting bal-
loon, and restenting) has been advocated for selected patients with
ISR. Furthermore, such devices have been rapidly embraced by the
interventional cardiology community as the result of their highly
appealing mechanistic properties. Nevertheless, uniformly, all
large-scale randomized trials have been unable to confirm the
suggested benefit of these alternative mechanical interventions
(1,3,4).
In this regard, Albiero et al. (1) should be congratulated for
carrying out the definitive study on the use of cutting balloon in
patients with ISR. The associated procedural-related advantages,
including a lower incidence of balloon slippage, however, remain of
major interest. In a previous study (5) we found that, in patients
with ISR, balloon slippage was associated with poorer acute and
long-term angiographic results. In the study by Albiero et al. (1),
although this phenomenon was not a predictor of restenosis in the
overall patient population, it would have been of great interest to
know the implications (both acute and long-term) of this finding
in patients treated with conventional balloon angioplasty. It is
quite possible that the appearance of this technical problem could
explain suboptimal results or residual dissections and, therefore,
the higher requirement of additional stenting in the balloon group.
Finally, although the cutting balloon was not superior to
conventional dilation in the entire series it would be of major
interest to know whether any specific subgroup of patients bene-
fited from the technique. Despite inherent problems with sub-
group analyses, identification of a subset of ISR patients likely to
benefit from this technique would be of enormous practical value.
Currently, most investigators favor the use of cutting balloon
during brachytherapy procedures to prevent geographical miss and
subsequently edge-restenosis. Nevertheless, once again, a recent
study failed to demonstrate long-term benefits after the use of this
device in ISR patients undergoing brachytherapy (6). Whether the
reported procedural advantages of using cutting balloon will
translate into clinical or angiographic benefit for patients with ISR
treated with drug-eluting stenting (7) remains speculative but
deserves prospective evaluation. Above all, it becomes clear that in
the rapidly evolving field of interventional cardiology the impetus
for adopting new devices, strategies, and ideas should be tempered
and balanced out by the so-called “evidence-based medicine.”
*Fernando Alfonso, MD, PhD
*H Clinico San Carlos
Interventional Cardiology
Plaza Cristo Rey
Madrid 28040
Spain
E-mail: falf@hotmail.com
doi:10.1016/j.jacc.2004.09.022
REFERENCES
1. Albiero R, Silber S, Di Mario C, et al. Cutting balloon versus
conventional balloon angioplasty for the treatment of in-stent resteno-
sis. Results from the Restenosis Cutting Balloon Evaluation Trial
(RECUT). J Am Coll Cardiol 2004;43:943–9.
2. Alfonso F, Pérez-Vizcayno MJ, Hernandez R, et al. Long-term outcome
and determinants of event-free survival in patients treated with balloon
angioplasty for in-stent restenosis. Am J Cardiol 1999;83:1268–70.
3. von Dahl J, Dietz U, Haager PK, et al. Rotational atherectomy does not
reduce recurrent in-stent restenosis. Results of the Angioplasty versus
Rotational atherectomy for Treatment of diffuse In-Stent restenosis
Trial (ARTIST). Circulation 2002;105:583–8.
4. Alfonso F, Zueco J, Cequier A, et al. A randomized comparison of
repeat stenting with balloon angioplasty in patients with restenosis after
coronary stenting. J Am Coll Cardiol 2003;42:796–805.
5. Gómez-Recio M, Morı´s C, Insa L, et al. Implications of the “water-
melon seeding” phenomenon during coronary interventions for in-stent
restenosis. Insights from the Restenosis Intrastent Balloon angioplasty
versus elective Stenting (RIBS) randomized trial (abstr). J Am Coll
Cardiol 2004;43 Suppl A:78A.
6. Kobayashi Y, Mehran R, Mintz GS, et al. Acute and long-term
outcomes of cutting balloon angioplasty followed by gamma brachy-
therapy for in-stent restenosis. Am J Cardiol 2003;92:1329–31.
7. Degertekin M, Regar E, Tanabe K, et al. Sirolimus-eluting stent for
treatment of complex in-stent restenosis: the first clinical experience.
J Am Coll Cardiol 2003;41:184–9.
2416 Correspondence JACC Vol. 44, No. 12, 2004
December 21, 2004:2410–9
